Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Phase 2 Completed 55 enrolled M.D. Anderson Cancer Center Ortho Biotech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if treatment with two types of chemotherapy combinations can help to control peripheral T-cell lymphoma.

Timeline

Start: 2003-09
Primary completion: 2015-07
Completion: 2015-07

Publications

Results Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov;171(4):509-16. doi: 10.1111/bjh.13628. Epub 2015 Aug 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	300 mg/m2	Intravenous
Subject	Cytarabine	Small molecule	3 g	Intravenous
Subject	Dexamethasone	Small molecule	40 mg	Intravenous
Subject	Doxorubicin	Other / unclassified	25 mg/m2	Intravenous
Subject	Methotrexate	Small molecule	200 mg/m2	Intravenous
Subject	Methotrexate	Small molecule	800 mg/m2	Intravenous
Subject	Vincristine	Small molecule	1.4 mg/m2	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	600 mg/m2	Intravenous
Background	G-CSF	Unknown	300 ug	Subcutaneous
Background	G-CSF	Unknown	480 ug	Subcutaneous

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Summary

Timeline

Publications

Drugs

Indications